Suppr超能文献

探索基于肼的小分子作为KDM4抑制剂的金属螯合剂。

Exploration of hydrazine-based small molecules as metal chelators for KDM4 inhibition.

作者信息

Saxton Angus J, Sterling Jayden, Hamilton Michael P, Abbassi Ramzi H, McCluskey Adam, Munoz Lenka, Baker Jennifer R

机构信息

Chemistry, School of Environmental and Life Sciences, The University of Newcastle Callaghan NSW 2308 Australia

Charles Perkins Centre and School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney Sydney NSW 2006 Australia

出版信息

RSC Med Chem. 2025 Jul 1. doi: 10.1039/d4md00305e.

Abstract

Hydrazines and related moieties are frequently employed in inhibitory compounds targeting iron-dependent dioxygenases such as the histone lysine demethylases (KDMs), which are promising targets in targeted epigenetic cancer therapies. Four compound libraries consisting of 81 compounds were synthesized and screened for inhibitory activity against KDM4A in an optimised AlphaScreen assay. Slight inhibition was observed for the series of 3-((2-benzoylhydrazono)methyl)benzoic acids that constituted library 1, with compounds 16, 17, 24, 28, and 38 exhibiting the most significant reductions in KDM4A activity at a screening concentration of 20 μM. Removal of the hydrazide carbonyl to generate a series of 3-((2-hydrazono)methyl)benzoic acids in library 2 proved detrimental to inhibitory activity except for compound 46. Evaluation of a series of 2-((2-benzoylhydrazono)methyl)benzoic acids and 2-((2-hydrazono)methyl)benzoic acids in library 3 revealed varied trends compared to matched library 1 and 2 counterparts, however, generally poor activity was observed for most compounds in this library. Masking of the carboxylic acid moiety with a methyl ester was explored in library 4 and resulted in overall reduced KDM4 inhibition compared to matched free acid counterparts in libraries 1, 2, and 3, however, compounds 70 and 72 exhibited markedly improved inhibitory activity with 72 being the most active analogue reported herein at <40% residual KDM4A activity at a screening concentration of 20 μM. Binding poses generated using MOE indicate effective metal chelation by either the carboxylic acid or hydrazine moiety in these compounds consistent with the observed inhibitory activity.

摘要

肼类及其相关部分常用于靶向铁依赖性双加氧酶的抑制性化合物中,例如组蛋白赖氨酸去甲基化酶(KDMs),它们是靶向表观遗传癌症治疗中有前景的靶点。合成了由81种化合物组成的四个化合物库,并在优化的AlphaScreen试验中筛选了对KDM4A的抑制活性。对于构成库1的一系列3 - ((2 - 苯甲酰肼基)甲基)苯甲酸,观察到轻微抑制,化合物16、17、24、28和38在20 μM的筛选浓度下表现出KDM4A活性最显著的降低。除化合物46外,在库2中去除酰肼羰基以生成一系列3 - ((2 - 肼基)甲基)苯甲酸被证明对抑制活性不利。与匹配的库1和2对应物相比,库3中一系列2 - ((2 - 苯甲酰肼基)甲基)苯甲酸和2 - ((2 - 肼基)甲基)苯甲酸的评估显示出不同的趋势,然而,该库中的大多数化合物通常活性较差。在库4中探索了用甲酯掩盖羧酸部分,与库1、2和3中匹配的游离酸对应物相比,导致KDM4抑制总体降低,然而,化合物70和72表现出明显改善的抑制活性,其中72是本文报道的最具活性的类似物,在20 μM的筛选浓度下残留KDM4A活性 < 40%。使用MOE生成的结合模式表明这些化合物中的羧酸或肼部分有效地螯合了金属,这与观察到的抑制活性一致。

相似文献

5
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.

本文引用的文献

4
Acylhydrazones and Their Biological Activity: A Review.酰腙及其生物活性:综述。
Molecules. 2022 Dec 9;27(24):8719. doi: 10.3390/molecules27248719.
8
Unravelling KDM4 histone demethylase inhibitors for cancer therapy.解析 KDM4 组蛋白去甲基化酶抑制剂在癌症治疗中的作用。
Drug Discov Today. 2021 Aug;26(8):1841-1856. doi: 10.1016/j.drudis.2021.05.015. Epub 2021 May 26.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验